Clinical trials: Cancer Refractory
Diffuse Large B-Cell Lymphoma
Mitoxantrone Hydrochloride Liposome Injection in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
A multicenter, single-arm, phase 2 study of mitoxantrone hydrochloride liposome injection in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
- Trial name
- NCT05875428
- Testing
- Mitoxantrone Hydrochloride Liposome Injection
- Where
- China
- Volunteers
- 104 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia
Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
This is a research study to find out if adding a new study drug called revumenib to commonly used chemotherapy drugs is safe and if they have beneficial effects in treating patients with acute myeloid leukemia (AML) or acute…
- Conditions
- Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Leukemia of Ambiguous Lineage
- Trial name
- NCT06177067
- Testing
- Revumenib, Venetoclax, Azacitidine
- Where
- 10 sites in United States
- Volunteers
- 24 people
- Sponsor
- St. Jude Children's Research Hospital
Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)
A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies
The purpose of this trial is to assess the efficacy, safety, tolerability, biologic activity, and pharmacokinetics of AMN107 in six groups of patients with one of the following conditions: Relapsed/refractory Ph+ Acute…
- Conditions
- Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), Hypereosinophilic Syndrome, Systemic Mastocytosis
- Trial name
- NCT00109707
- Testing
- Nilotinib
- Where
- 101 sites in United States, Australia and 20 more
- Volunteers
- 507 people
- Sponsor
- Novartis Pharmaceuticals
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
The primary objective of this study is to determine the maximum tolerated doses (MTD) and the recommended Phase 2 dose (RP2D), and safety, tolerability, and efficacy of zanubrutinib in combination with lenalidomide in…
- Trial name
- NCT04436107
- Testing
- Zanubrutinib, Lenalidomide
- Where
- 10 sites in China
- Volunteers
- 66 people
- Sponsor
- BeiGene
Childhood Solid Tumor
Haploidentical Stem Cell Transplantation and IL-15 NK Cell Infusion for Paediatric Refractory Solid Tumours
The investigators propose a new antitumor cell therapy for treating childhood refractory solid tumours. The aim of this study is explore the graft versus tumour effect mediated by allogenic natural killer cells (NKs).
- Trial name
- NK (NCT01337544)
- Testing
- HAPLOIDENTICAL IL-15 STIMULATED NK CELLS
- Where
- Spain
- Volunteers
- 6 people
- Sponsor
- Hospital Infantil Universitario Niño Jesús, Madrid, Spain
Breast Cancer, Lung Cancer
IDO Inhibitor Study for Relapsed or Refractory Solid Tumors
This study provides an early evaluation of an entirely new class of small molecule agents directed at disruption or elimination of tumor tolerance, a phenomenon now demonstrated to be involved in the growth of many solid tumors.
- Conditions
- Breast Cancer, Lung Cancer, Melanoma, Pancreatic Cancer
- Trial name
- D-1MT (NCT00739609)
- Testing
- 1-methyl-D-tryptophan
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- NewLink Genetics Corporation
Solid Tumor Refractory to Standard Therapy
Single-dose Escalation Study of SQ-001 Infusion to Characterize the PK Profiles of Major Sentinel Compounds in Healthy Adult Volunteers in US
This is a single-center, double-blind, single-dose escalation study in healthy volunteers.
- Trial name
- NCT04026321
- Testing
- SQ001 125mL/day, SQ001 250mL/day, SQ001 500mL/day
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Livzon Pharmaceutical Group Inc.
Solid Tumors, Cancer
Phase I Study of Oral DFP-11207 in Solid Tumors
This is a first-in-human, open label, single arm, sequential dose escalation and expansion study of oral DFP-11207 in patients with advanced solid tumors.
- Trial name
- NCT02171221
- Testing
- Oral DFP-11207
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Delta-Fly Pharma, Inc.
Refractory Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia
Clinical Study of LILRA6 CAR-T for the Treatment of R/R Acute Myeloid Leukemia
This study aims to evaluate the safety and efficacy of LILRA6-directed chimeric antigen receptor T cells (LILRA6 CAR-T cells) in patients with refractory or relapsed acute myeloid leukemia(AML).
- Trial name
- NCT07263906
- Testing
- Anti-LILRA6 CAR-T cells
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Hepatocellular Carcinoma
FMT in IT-refractory HCC - FAB-HCC Pilot Study
This single-center, pilot study (phase IIa) will evaluate the safety, feasibility, and efficacy of FMT from patients with HCC who responded to PD-(L)1-based immunotherapy to patients with HCC who failed to respond to…
- Trial name
- NCT05750030
- Testing
- FMT combined with Atezolizumab plus Bevacizumab
- Where
- Austria
- Volunteers
- 12 people
- Sponsor
- Medical University of Vienna
Chronic Lymphocytic Leukemia
A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL
This is an open-label, multicenter, Phase II study to investigate the efficacy and safety of venetoclax in combination with Rituximab/hyaluronidase human in participants with relapsed or refractory chronic lymphocytic leukemia…
- Trial name
- NCT03467867
- Testing
- Venetoclax, Rituximab, Rituximab/Hyaluronidase Human
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Georgetown University
Gastro Esophageal Reflux, Barrett Esophagus
Confocal Endomicroscopy for Permeability of Esophageal Wall in Refractory Gastroesophageal Reflux Disease (GERD)
Confocal Endomicroscopy for Permeability of Esophageal Wall in Refractory Gastroesophageal Reflux Disease (GERD)
- Conditions
- Gastro Esophageal Reflux, Barrett Esophagus, Erosive Esophagitis
- Trial name
- NCT03228407
- Testing
- Confocal endomicroscopy, Endoscopic biopsies, Mucosal impedance (MI)
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- McGuire Research Institute
EGFR NP_005219.2:p.S492R, KRAS Gene Mutation
Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer
This phase II clinical trial studies how well panitumumab with or without trametinib works in treating patients with stage IV colorectal cancer.
- Conditions
- EGFR NP_005219.2:p.S492R, KRAS Gene Mutation, MAP2K1 Gene Mutation, Metastatic Colorectal Adenocarcinoma
- Trial name
- NCT03087071
- Testing
- Laboratory Biomarker Analysis, Panitumumab, Trametinib
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- M.D. Anderson Cancer Center
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma
This phase II trial studies how well selumetinib works in treating patients with multiple myeloma, a type of cancer in which a specific protein is over active.
- Trial name
- NCT01085214
- Testing
- Laboratory Biomarker Analysis, Selumetinib
- Where
- 9 sites in United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
the Efficacy and Safety of CLAE in R/R T-ALL/LBL
To evaluate the efficacy and safety of CLAE regimen (cladribine + cytarabine + etoposide) in the treatment of relapsed/refractory T-ALL/LBL.
- Trial name
- NCT04679506
- Testing
- Cladribine
- Volunteers
- 50 people
- Sponsor
- Peking University Third Hospital
CLL, B-cell Non Hodgkin Lymphoma
Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL
This study will be a standard 3+3 design with a lead in of TGR-1202 at dose of 600mg (dose level 1) or 800mg daily (dose level 2) for 6 weeks, i.e.
- Trial name
- NCT03283137
- Testing
- TGR-1202, Pembrolizumab
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of Chicago
Solid Tumor Refractory to Conventional Treatment
Phase I Study of FXS887 in the Treatment of Solid Tumors
This is a single-arm, open-label, dose-escalation and dose-expansion Phase I clinical trial evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of FXS887 in patients with advanced solid tumors.
- Trial name
- FXS887-I101 (NCT07345637)
- Testing
- FXS887
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes
Tipifarnib in Treating Patients With Myelodysplastic Syndromes
This phase I trial studies the side effects and best dose of tipifarnib in treating patients with myelodysplastic syndromes. Tipifarnib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Refractory Anemia
- Trial name
- NCT00005845
- Testing
- tipifarnib, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Carcinoma
MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritoneal Carcinoma
The purpose of this study is to evaluate the anti-tumour activity of alisertib (MLN8237) in the treatment of participants with platinum-refractory or platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal…
- Trial name
- NCT00853307
- Testing
- Alisertib
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Pain, Intractable
Effectiveness of Ketamine in Malignant Neuropathic Pain Relief
To see whether the addition of low-dose ketamine to a subcutaneous morphine infusion improves analgesia in patients with neuropathic cancer pain.
- Trial name
- KETA-1 (NCT01951911)
- Testing
- Ketamine
- Where
- Norway
- Sponsor
- Haukeland University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.